GlycoMimetics (GLYC) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021
March 3, 2022 7:30 AM ESTPost year-end 2022 remains target for top-line data release of GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) National Cancer Institute (NCI) to conduct post-Phase 2 interim analysis based on event-free survival for the NCI-sponsored Phase 2/3 registration trial evaluating uproleselan in older, newly diagnosed AML patients fit for chemotherapy Apollomics Phase 3 uproleselan trial in Greater China initiated in November 2021 Investigational New Drug (IND) activities continued for GMI-1687 for treatment of acute vaso-occlusive crisis (VOC) of sickle cell disease; IND submission targeted for first half... More
